Introduction
============

Autologous fat grafting is a promising surgical technique for soft tissue augmentation, reconstruction and rejuvenation. Fat tissue is abundant, readily available and relatively low cost, and can be harvested with minimal trauma to the donor site. Fat grafts have been extensively used in numerous fields, including the treatment of Romberg\'s disease, depressed scars, wrinkles, senile atrophy, pitting acne, breast augmentation, and hand and face rejuvenation ([@b1-mmr-16-03-3069]). Despite these uses, transplanted fat often has a low survival rate, and adipose tissue can be quickly resorbed and replaced with fibrous tissue and oil cysts ([@b2-mmr-16-03-3069]--[@b4-mmr-16-03-3069]). Fat graft retention rates have been reported to range between 10 and 90% ([@b5-mmr-16-03-3069],[@b6-mmr-16-03-3069]). Several theories have been suggested to explain this phenomenon ([@b7-mmr-16-03-3069],[@b8-mmr-16-03-3069]). At present, the generally accepted explanation for the decreasing fat volume is insufficient blood supply following transplantation ([@b8-mmr-16-03-3069]--[@b10-mmr-16-03-3069]). Therapeutic approaches that stimulate angiogenesis, including co-transplanting fat with proangiogenic growth factors, endothelial progenitor cells and mesenchymal stem cells (MSCs) from various sources, have significantly improved fat graft retention ([@b11-mmr-16-03-3069]--[@b16-mmr-16-03-3069]). Such co-transplanted cells likely promote neovascularization via the paracrine action of proangiogenic factors, a mechanism that has also been observed during the treatment of other ischemic diseases ([@b17-mmr-16-03-3069]--[@b19-mmr-16-03-3069]).

In addition to cell-based therapies for the treatment of ischemic diseases, interest in the vesicles released by these cultured cells has garnered interest. Extracellular vesicles (EVs), which are released by almost all cells, are normally comprised of three types: Microvesicles, exosomes and apoptotic bodies ([@b20-mmr-16-03-3069]). Furthermore, EVs have been detected in various body fluids, including blood, malignant pleural effusion, urine, saliva and cerebrospinal fluid ([@b21-mmr-16-03-3069]). Previously, EVs were considered inert cellular debris, the consequence of cell damage or the result of dynamic plasma membrane turnover. However, EVs have more recently been reported to serve an important role in intercellular communication ([@b22-mmr-16-03-3069]). The structure of EVs consists of a lipid bilayer membrane, similar to the cellular membrane, which envelops host-specific proteins, mRNAs and microRNAs. Numerous studies have investigated the role of EVs in tissue repair and regeneration ([@b18-mmr-16-03-3069],[@b22-mmr-16-03-3069],[@b23-mmr-16-03-3069]). In addition, animal studies have demonstrated that the systemic application of EVs derived from cultured bone marrow MSCs (BMSC-EVs) protects cells during acute kidney injury and cardiovascular disease ([@b18-mmr-16-03-3069],[@b23-mmr-16-03-3069],[@b24-mmr-16-03-3069]). It has been suggested that BMSC-EVs may protect injured tissues by inducing angiogenesis ([@b18-mmr-16-03-3069],[@b24-mmr-16-03-3069]).

Based on the proangiogenic potential of BMSC-EVs, the present study hypothesized that co-transplantation of fat with BMSC-EVs during grafting would prevent fat cell death and stimulate neovascularization, thus helping to prevent graft resorption. To test this hypothesis, BMSC-EVs were collected from the supernatant of cultured rat BMSCs using ultra-centrifugation. Subsequently, human fat tissue, combined with various concentrations of BMSC-EVs, was subcutaneously injected into nude mice, and the effects were evaluated 12 weeks post-transplantation.

Materials and methods
=====================

### Cell culture and isolation of EVs

A total of 80 male Wistar rats (4 weeks old) weighing 90--110 g were purchased from the Shanghai Chuansha Experimental Animal Raising Farm (Shanghai, China). The animal study protocols were approved by the Animal Care and Experiment Committee of Shanghai Jiao Tong University School of Medicine (Shanghai, China). They were housed under a temperature of 20--26°C, a relative humidity of 40--70% and a day/night cycle of 12/12 h, with free access to food and water. BMSCs were cultured as previously described ([@b25-mmr-16-03-3069]). Briefly, rat bone marrow cells were extracted from the femurs of male Wistar rats. To remove the majority of the non-adherent blood cells, primary culture of bone marrow cells was performed by seeding cells at 1.6×10^4^ cells/cm^2^ in Dulbecco\'s modified Eagle\'s medium (DMEM; Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Hyclone; GE Healthcare Life Science, Logan, UT, USA) and 0.2% penicillin/streptomycin (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) at 37°C. The medium was changed every 3 days. After 6--7 days of culture the primary adherent cells (P0) were harvested using trypsin/EDTA (0.25% w/v trypsin and 0.02% EDTA; Invitrogen; Thermo Fisher Scientific, Inc.), and were subcultured at 1.6×10^4^ cells/cm^2^ in a 10-cm diameter tissue culture dish in 10 ml DMEM containing 10% FBS. The cells were passaged in the same manner every 3 days. Passage 4 cells were evaluated for typical MSC characteristics, including the cell surface marker expression profile and multi-lineage differentiation potential (data not shown), and were used for the collection of EVs. Once the cells reached 70% confluence, they were cultured in serum-free media under hypoxic conditions (94% N2, 5% CO~2~ and 1% O2) for 48 h. The culture supernatants were collected and centrifuged at 2,000 × g for 20 min at 4°C to remove any large particles of debris. After an additional centrifugation at 100,000 × g for 1 h at 4°C, the pellet was washed twice in PBS ([@b26-mmr-16-03-3069]). The collected BMSC-EVs were then resuspended in 50 µl PBS and stored at −80°C for use in the subsequent experiments. The amount of BMSC-EVs was determined by measuring the total protein content using the Bradford method (Sigma-Aldrich; Merck KGaA).

### Scanning electron microscopy

The EVs were suspension-fixed in 4% paraformaldehyde dissolved in PBS for 12 h at 4°C. Subsequently, the EVs were dehydrated through a graded series of ethanol/water (50--100%, v/v) solutions, and then dried at the critical point. The samples were gold-sputtered and examined under a Hitachi S-4800 field emission scanning electron microscope (Hitachi, Tokyo, Japan) at an acceleration voltage of 10 kV.

### Characterization of the BMSC-EVs

The size distribution of the EVs was measured using a particle size analyzer (Nicomp 380 ZLS; Particle Sizing Systems, Port Richey, FL, USA) ([@b27-mmr-16-03-3069]). The samples were illuminated by red laser light (15 mW, 635 nm), and a digital camera captured the scattered light. The EVs were automatically tracked and sized, based on Brownian motion and their diffusion coefficient. The results are displayed as representative size distribution profiles.

A phenotypic profile of the EVs was determined using bead-based flow cytometry. Briefly, the BMSC-EVs were bound to aldehyde/sulfate latex beads (4 mm; Molecular Probes; Thermo Fisher Scientific, Inc.) suspended in 2-(N-morpholino) ethane sulfonic acid (MES) buffer (0.025 M MES, 0.154 M NaCl; pH 6.0) overnight at 4°C with gentle agitation. The reaction was terminated by incubation for 30 min with 200 mM glycine at room temperature, to saturate any remaining free binding sites on the beads. After two washes in PBS containing 4% FBS, the BMSC-EVs-coated beads were stained with the following antibodies: Fluorescein isothiocyanate (FITC)-or phycoerythrin (PE)-conjugated anti-cluster of differentiation CD81 (catalog no. 559519, 1:400), CD63 (catalog no. 551458, 1:200), CD29 (catalog no. 555005, 1:200), CD90 (catalog no. 554894, 1:200), CD45 (catalog no. 559135, 1:200), CD31 (catalog no. 555026, 1:200) purchased from BD Biosciences (San Diego, CA, USA), with or without the following secondary antibodies: PE streptavidin; catalog no. 554061; 1:200 and goat anti-mouse 488; catalog no. A11001; 1:200, at 4°C overnight. Beads without BMSC-EVs were prepared to determine the forward and side scatter signals of the beads. All data were collected on an Epics Altra Hypersort™ system (Beckman Coulter, Inc., Brea, CA, USA) and were analyzed with FlowJo Software 7.6.1 (FlowJo, LLC, Ashland, OR, USA).

### Cellular uptake of BMSC-EVs

BMSC-EVs were labeled with Cell Tracker™ CM-Dil (Thermo Fisher Scientific, Inc.). Briefly, 1 µl cell-labeling solution was added to 200 µg EVs suspended in 1 ml PBS, and was incubated for 20 min at 37°C. Subsequently, the mixture was centrifuged at 100,000 × g for 1 h at 4°C, the supernatants were removed, and the BMSC-EVs were gently resuspended in PBS. This washing procedure was repeated 3 times.

Human umbilical vein endothelial cells (HUVECs) were purchased from ScienCell Research Laboratories (Carlsbad, CA, USA), and were cultured in DMEM supplemented with 10% FBS and 1% penicillin-streptomycin at 37°C in a humidified incubator (5% CO~2~). Following incubation with CM-Dil-labeled BMSC-EVs (20 µg/ml) for 2, 4 or 6 h, the cells were washed twice with PBS, fixed in 4% paraformaldehyde and stained with DAPI. The cells were then observed under a confocal microscope (Leica TCS SP5; Leica Microsystems GmbH, Wetzlar Germany). The images were collected and merged using Image-Pro Plus 6 (Media Cybernetics, Inc., Rockville, MD, USA).

### Cell viability

HUVECs (1.0×10^3^ cells/well) were plated in 96-well plates (3 wells/group) and treated with 50 or 100 µg/ml BMSC-EVs for 6 days. At the indicated time-points (1, 2, 3, 4 and 5 days), cell viability was determined using Cell Counting Kit-8 (CCK8; Dojindo Molecular Technologies, Inc., Kumamoto, Japan) according to the manufacturer\'s protocol. The absorbance was measured at 450 nm using an ELISA reader (Bio-Tek Instruments, Inc., Winooski, VT, USA). All experiments were repeated ≥3 times.

### Tube formation

Matrigel (BD Biosciences) was thawed and pipetted into a 24-well culture plate, and was incubated at 37°C for 30 min to allow solidification. HUVECs (5×10^4^) were treated with 50 or 100 µg/ml BMSC-EVs for 12 h at 37°C. Tube formation was examined by phase-contrast microscopy (Olympus Corporation, Tokyo, Japan), and the number of network structures was quantified using Image-Pro Plus 6 (Media Cybernetics, Inc.). The data were statistically analyzed using GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla, CA, USA). All experiments were repeated ≥3 times.

### Cell migration

Cell migration was assessed by scratch assays. Briefly, HUVECs were grown to confluence (2×10^5^ cell/ml) in a 6-well plate and a scratch was made in the cell field using a 1,000 µl pipette tip. The wells were washed with PBS to remove any debris and incubated with 50 or 100 µg/ml BMSC-EVs for 12 h at 37°C. Bright-field microscopy images were then collected (Olympus Corporation) and cell migration was assessed using Image-Pro Plus 6 (Media Cybernetics, Inc.). The data were statistically analyzed using GraphPad Prism 5 software (GraphPad Software, Inc.). All experiments were repeated ≥3 times.

### Isolation and preparation of human fat tissue

During the period of June 2015 to November 2016, human liposuction aspirates were obtained from 10 healthy female donors aged from 28 to 40 who underwent liposuction of the abdomen at Shanghai 9th People\'s Hospital (Shanghai, China). Each patient provided written informed consent. The protocol for this study was approved by the Ethics Committee of Shanghai Jiao Tong University School of Medicine. Prior to initiation of the procedure, the liposuction site was infiltrated with tumescent solution containing 0.08% lidocaine and a 1: 500,000-unit dilution of epinephrine. Under sterile conditions, the lipid part of the fat aspirate was rinsed with sterile PBS to remove blood, saline and the local anesthetic. The adipose portion of the liposuction aspirate was placed in an upright position to obtain a clear separation of the fluids and oil. The upper (oil) and lower (blood and infiltration liquids) layers were removed, and the middle portion containing the fat particles was immediately transferred to 50 ml centrifuge tubes and stored at 4°C until further use.

### Animal model and study design

Female BALB/c-nu nude mice (age, 6 weeks; weight, 14--17 g) were obtained from the Shanghai Chuansha Experimental Animal Raising Farm (Shanghai, China). Mice were kept at a temperature of 20--26°C, a relative humidity of 40--70% and a day/night cycle of 12/12 h, with food and water *ad libitum*, and a total of 27 mice were randomly divided into three groups (n=9 mice/group). In the control (untreated) group, mice were injected with 1 ml human fat and 200 µl sterile PBS; in the low-dose EV group, mice were injected with 1 ml human fat and 200 µl sterile PBS containing 50 µg BMSC-EVs; in the high-dose EV group, mice were injected with 1 ml human fat and 200 µl sterile PBS containing 100 µg BMSC-EVs.

The scalp of the mouse was chosen as the recipient site for fat injection due to the absence of subcutaneous fat in this area. The mice were anesthetized with 0.2 ml 5% chloral hydrate and a subcutaneous tunnel was created by antegradely passing a needle from the dorsalis to the scalp. Fat was then injected using a 14 G needle in the retrograde direction while pulling the needle out. Following injection, the skin incisions were closed with \#6/0 non-absorbable sutures. A total of 12 weeks following transplantation, the mice were sacrificed and the grafts were harvested. Macroscopic inspection revealed that the fat grafts were surrounded by a thin envelope, making it easy to isolate them from the host tissue.

### Graft volume

The harvested fat tissue grafts were weighed on a balance and their volumes were determined according to the liquid overflow method ([@b13-mmr-16-03-3069]). Briefly, a graduated cylinder was filled with PBS, the fat tissues were immersed in the cylinder, and the fat volume was determined by the consequent increase in buffer volume.

### Histology and immunohistochemistry

Following volume determination, the grafts removed from the scalp were fixed in 4% paraformaldehyde for 12 h, embedded in paraffin, and cut into sections (size, 8 µm). These sections were stained with hematoxylin for 15--30 min and eosin for 3--5 min (H&E stain) for structural analysis and Masson\'s staining (acid fuchsin stain for 5--10 min and aniline blue stain for 5 min) for analysis of the fibrotic area. A total of 5 randomly selected fields from each sample (n=3 per group) were imaged under an inverted microscope (Olympus Corporation).

Immunohistochemical staining was performed according a method previously published ([@b25-mmr-16-03-3069]). In brief, paraffin-embedded sections (8 mm thick) were incubated with goat anti-CD31 antibody (catalog no. sc-1506; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) overnight at 4°C, followed by incubation with a horseradish peroxidase-conjugated rabbit anti-goat secondary antibody (catalog no. E0466; Dako; Agilent Technologies, Inc.) at room temperature for 30 min, and colorization with 3,3′-diaminobenzidine tetrahydrochloride (Dako; Agilent Technologies, Inc.) at room temperature for 3 min. A total of 5 randomly selected fields from each sample (n=3/group) were imaged under a light microscope (Nikon Eclipse 90i; Nikon Corporation, Tokyo, Japan). The number of CD31-positive capillaries was calculated using Image-Pro Plus 6 (Media Cybernetics, Inc.), and the data were statistically analyzed using GraphPad Prism 5 software (GraphPad Software, Inc.) ([@b25-mmr-16-03-3069]).

### Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

Total RNA from the control and low-dose EV groups were extracted and reverse transcribed to obtain cDNA, as previously described ([@b25-mmr-16-03-3069]). RT-qPCR was performed using a Power SYBR-Green PCR Master Mix (Applied Biosystems; Thermo Fisher Scientific, Inc.) in an Mx3000P qPCR system thermal cycler (Stratagene; Agilent Technologies, Inc., Santa Clara, CA, USA). Cycling conditions were as follows: An initial predenaturation step at 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 30 sec, annealing at 60°C for 30 sec and extension at 72°C for 45 sec. The primers used for detection of the following proangiogenic factors: Platelet-derived growth factor α (PDGF-A), platelet-derived growth factor receptor α (PDGFR-A), vascular endothelial growth factor A (VEGF-A) and transforming growth factor β (TGF-β) are listed in [Table I](#tI-mmr-16-03-3069){ref-type="table"}. Gene expression was normalized to GAPDH expression according to the 2^−∆∆Cq^ method ([@b28-mmr-16-03-3069]). Each sample was tested in triplicate, and 3 independent experiments were performed.

### Statistical analysis

The data were statistically analyzed using GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla, CA, USA). Data are expressed as the mean ± standard deviation. The significance of differences between groups was assessed by Student\'s t-test or one-way analysis of variance followed by the Newman-Keuls post hoc test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Characterization of BMSC-EVs

To determine whether co-transplantation of fat with BMSC-EVs improves fat graft retention, EVs were isolated from the supernatants of rat BMSCs and were characterized. Scanning electron microscopy demonstrated that the EVs were heterogeneous with a spheroid-shaped morphology ([Fig. 1A](#f1-mmr-16-03-3069){ref-type="fig"}). Particle size analysis indicated that the average EV diameter was 228.4±28.8 nm, with a range between 40 and 300 nm ([Fig. 1B](#f1-mmr-16-03-3069){ref-type="fig"}), thus suggesting that the EVs comprised a mixture of exosomes and microvesicles. Flow cytometry demonstrated that the EVs expressed high levels of the following BMSC-positive and EV-positive markers: CD90, CD29, CD81 and CD63, but not of the endothelial and hematopoietic cell markers: CD31 and CD45 ([Fig. 1C and D](#f1-mmr-16-03-3069){ref-type="fig"}). These findings indicated that the EVs were of BMSC origin.

### Cellular uptake of BMSC-EVs

In order to determine whether the BMSC-EVs interact with vascular endothelial cells, HUVECs were incubated with CM-Dil-labeled BMSC-EVs and observed by confocal microscopy. Following a 2-h incubation, CM-Dil was observed on the cell surface. With increasing incubation time, more fluorescent dye accumulated in the cytoplasm, eventually reaching a maximal signal at 6 h ([Fig. 2](#f2-mmr-16-03-3069){ref-type="fig"}). These results indicated that the EVs were internalized by HUVECs.

### BMSC-EVs promote viability, migration and tube formation of HUVECs

To determine the effects of BMSC-EVs on endothelial cells, HUVECs were exposed to 50 or 100 µg/ml BMSC-EVs, and their cell viability, migration and tube-forming capabilities were assessed. As presented in [Fig. 3A](#f3-mmr-16-03-3069){ref-type="fig"}, 100 µg/ml EVs increased cell viability by \~1.3-fold compared with the control group after 5 days; however, there were no significant differences between the low (50 µg/ml) and high dose (100 µg/ml) treatment groups. An *in vitro* tube formation assay was conducted to assess the angiogenic effects of BMSC-EVs; the results demonstrated that more vessel-like structures were observed following EV treatment, in a dose-dependent manner ([Fig. 3B and C](#f3-mmr-16-03-3069){ref-type="fig"}). Quantitative and statistical analysis demonstrated that the high dose EV-treated HUVECs formed 3,419±97 vessel-like structures per section, whereas the control cells formed 2,553±107, thus suggesting a \~1.34-fold increase in vessel-like structures following EV treatment ([Fig. 3C](#f3-mmr-16-03-3069){ref-type="fig"}). In addition, the cell migration assay indicated that treatment of HUVECs with high dose BMSC-EVs resulted in rapid closure of the scratched area, which was \~1.39-fold faster compared with in the non-treated HUVECs; this effect was dose-dependent ([Fig. 3D and E](#f3-mmr-16-03-3069){ref-type="fig"}). These results suggested that BMSC-EVs may promote endothelial cell viability, migration and tube-forming capabilities *in vitro*, indicating that BMSC-EVs may exert angiogenesis-promoting activity.

### BMSC-EVs improve fat graft retention

To evaluate the effects of BMSC-EVs on the retention of transplanted fat grafts in animals, human fat prepared from liposuction aspirates was co-injected with BMSC-EVs into nude mice. A total of 12 weeks post-transplantation, all 27 mice in the control, low-dose EV and high-dose EV groups survived. No inflammation or abscesses were observed in the surgical areas. Subsequently, the mice were sacrificed and the fat grafts were harvested. A total of 5 representative images of grafts from each group (n=9) are presented in [Fig. 4A](#f4-mmr-16-03-3069){ref-type="fig"}. The grafts in the EV-treated groups appeared larger than those in the non-treated group ([Fig. 4A](#f4-mmr-16-03-3069){ref-type="fig"}). Statistical analysis (n=9/group) demonstrated that average fat volume in the control, low-dose EV and high-dose EV groups was 0.2018±0.0258, 0.3283±0.0368 and 0.3689±0.0241 ml, respectively, whereas the average fat weight in these groups was 0.1902±0.0252, 0.3166±0.0363 and 0.3297±0.0228 g, respectively. These results suggested that EV treatment increased graft retention ([Fig. 4B and C](#f4-mmr-16-03-3069){ref-type="fig"}).

The graft structure was further analyzed by H&E and Masson staining after sectioning. As presented in [Fig. 5](#f5-mmr-16-03-3069){ref-type="fig"}, all of the grafts contained intact adipocytes, fibrous tissue and vacuoles. The grafts from the EV-treated groups had more intact and nucleated adipocytes with relatively fewer fibers and vacuoles, whereas more vacuoles were observed in the control group. No differences were observed between the low- and high-dose groups. These observations suggested that BMSC-EVs may enhance adipose tissue regeneration post-transplantation.

### BMSC-EVs promote fat retention through neovascularization

In the animal model, BMSC-EVs appeared to improve graft retention by promoting adipose tissue regeneration; therefore, the present study examined whether BMSC-EVs may facilitate neovascularization, which is an indispensable process for tissue regeneration. To detect CD31-positive capillaries, harvested fat tissue grafts were subjected to immunohistochemical staining with an anti-CD31 antibody. An increased number of CD31-positive capillaries was observed in the EV-treated groups compared with in the control group ([Fig. 6](#f6-mmr-16-03-3069){ref-type="fig"}). Capillary density (vessel number per field) was calculated from 5 randomly selected fields in each sample from the control, low-dose EV and high-dose EV groups; capillary density was 6.20±4.07, 19.80±2.91 and 19.20±1.99, respectively, indicating that treatment with EVs may promote neovascularization ([Fig. 6](#f6-mmr-16-03-3069){ref-type="fig"}). Subsequently, the gene expression levels of proangiogenic factors were analyzed in the fat grafts by RT-qPCR. The expression levels of PDGF-A (3.306±0.65-fold), PDGFR-A (4.601±0.73-fold), VEGF-A (1.970±0.16-fold), and TGF-β (10.310±2.49-fold) were increased in the 50 µg/ml EV-treated group compared with in the control group ([Fig. 7](#f7-mmr-16-03-3069){ref-type="fig"}). These results suggested that BMSC-EVs may promote neovascularization by stimulating the secretion of proangiogenic factors.

Discussion
==========

Free fat grafting is an advantageous technique that may be used as a contouring tool in reconstructive and cosmetic surgical procedures; however, its use is limited by the unpredictable and poor long-term retention of the transplanted fat ([@b4-mmr-16-03-3069]). Although numerous methods for improving fat graft survival have been investigated, further improvements are still required.

At present, the exact mechanisms underlying fat graft survival remain unclear. One generally accepted mechanism leading to graft loss is a lack of adequate revascularization of the fat post-transplantation. Karacaoglu *et al* ([@b9-mmr-16-03-3069]) reported that fat graft survival was greatest in the supramuscular layer, and indicated that fat grafts used in relatively more vascular areas underwent lower rates of resorption. Eto *et al* ([@b7-mmr-16-03-3069]) demonstrated that adipocytes died as early as the first day after ischemia, endothelial cells died second, and finally adipose-derived stromal cells (ADSCs) died on day 3. Furthermore, Aygit *et al* ([@b29-mmr-16-03-3069]) revealed that revascularization of fat grafts occurred 48 h post-transplantation, indicating that it is too late for the survival of adipocytes. Various approaches for accelerating angiogenesis have been successfully undertaken to enhance fat survival post-transplantation, including the administration of basic fibroblast growth factors, interleukin-8 and erythropoietin ([@b11-mmr-16-03-3069],[@b30-mmr-16-03-3069],[@b31-mmr-16-03-3069]); VEGF-based gene therapy ([@b8-mmr-16-03-3069],[@b32-mmr-16-03-3069]); and endothelial cell and MSC therapies ([@b13-mmr-16-03-3069],[@b16-mmr-16-03-3069],[@b33-mmr-16-03-3069]).

EVs released by MSCs have recently been reported to exert proangiogenic effects in numerous ischemic animal models ([@b18-mmr-16-03-3069],[@b34-mmr-16-03-3069]). The present study demonstrated that BMSC-EVs stimulated neovascularization and improved retention of transplanted fat grafts in a nude mice model. The present results confirmed that EVs were of BMSC origin, as the cells expressed high levels of the BMSC-positive markers, CD81, CD63, CD90 and CD29, and were negative for the endothelial and hematopoietic cell markers, CD31 and CD45 ([Fig. 1C and D](#f1-mmr-16-03-3069){ref-type="fig"}). Confocal microscopy demonstrated that the BMSC-EVs interacted with endothelial cells *in vitro* ([Fig. 2](#f2-mmr-16-03-3069){ref-type="fig"}). Furthermore, the BMSC-EVs improved HUVEC *in vitro* cell viability, migration and tube formation, demonstrating the proangiogenic potential of BMSC-EVs ([Fig. 3](#f3-mmr-16-03-3069){ref-type="fig"}). Based on these findings, the effects of BMSC-EVs on free fat grafts were investigated in an animal model. The grafts from the EV-treated groups had higher tissue volume and weight, and improved histology, indicating a better overall survival than those in the control group at 12 weeks post-transplantation ([Figs. 4](#f4-mmr-16-03-3069){ref-type="fig"} and [5](#f5-mmr-16-03-3069){ref-type="fig"}). Immunohistochemical and RT-qPCR analyses also supported the hypothesis that the observed improvement in retention of fat graft weight and volume was attributable to the induction of angiogenesis ([Figs. 6](#f6-mmr-16-03-3069){ref-type="fig"} and [7](#f7-mmr-16-03-3069){ref-type="fig"}). These observations are also in agreement with the findings of previous studies, demonstrating a link between neovascularization and improved fat graft survival ([@b8-mmr-16-03-3069],[@b16-mmr-16-03-3069],[@b35-mmr-16-03-3069]).

In addition to neovascularization, the importance of adipogenesis for long-term retention of transplanted fat has been implicated. Previous *in vivo* studies have demonstrated that the majority of adipocytes in free grafts die shortly after transplantation, whereas only ADSCs survive ([@b7-mmr-16-03-3069],[@b36-mmr-16-03-3069],[@b37-mmr-16-03-3069]). In the 'three zone' theory suggested by Yoshimura *et al* ([@b38-mmr-16-03-3069]), the survival of fat grafts is largely dependent on adipose tissue regeneration post-transplantation, and CD34-positive cells are very likely the seed cells for adipogenic progression. Therefore, recent studies ([@b14-mmr-16-03-3069],[@b39-mmr-16-03-3069]) have focused on the therapeutic effects of adipose-derived cells, including stromal vascular fraction and ADSCs, on fat grafts. These cells may improve tissue outcomes by increasing the vascularity and the secretion of growth factors that improve tissue survival. Yoshimura *et al* ([@b40-mmr-16-03-3069]) reported that ADSCs are able to enhance angiogenesis and improve the survival rate of non-vascularized grafted fat. In addition, these cells may function as seed cells for adipogenesis. Compared with these cell-based therapies, BMSC-EVs serve a proangiogenic role, but do not undergo adipocyte differentiation. However, the present study demonstrated that the improvements in fat graft retention achieved by BMSC-EVs were as good as those from cell-based therapies ([@b16-mmr-16-03-3069],[@b39-mmr-16-03-3069]), indicating that revascularization is necessary for free fat grafting. This finding is in agreement with a recent study, which suggested that ADSCs are involved in the process of graft revascularization via paracrine action, but do not undergo significant adipogenic differentiation ([@b41-mmr-16-03-3069]).

With respect to clinical implications, cross-species MSCs have been successfully used in various *in vivo* animal models. In the nude mice model system used in the present study, human fat with EVs isolated from rat BMSCs was transplanted into the mice. In addition, Li *et al* ([@b42-mmr-16-03-3069]) identified 94 reports of *in vivo* cross-species administration of MSCs in various experimental models. Although the majority of these studies involved human MSCs, pig, rat or guinea pig MSCs were also occasionally used. A total of 93.6% of the cases confirmed that the MSCs were successfully engrafted and functioned well in the different species, with only 6.4% of cases reporting failure. In the present study, rat BMSC-EVs were internalized by HUVECs and promoted their viability, migration and tube-forming capabilities *in vitro*. In the nude mice experiments, the results indicated that rat BMSC-EVs improved the retention of human fat grafts, which suggests that BMSC-EVs function across species barriers, in accordance with a previous report that rat MSCs prolonged xenogenic skin graft survival in mice ([@b43-mmr-16-03-3069]).

In conclusion, the present study is the first, to the best of our knowledge, to demonstrate that co-transplantation of fat grafts with BMSC-EVs improves the long-term retention and transplanted fat quality in a mouse model. In addition, the present findings suggested that this beneficial effect is likely mediated by the proangiogenic effects of BMSC-EVs. These results suggested that effective employment of BMSC-EVs may have potential as a therapeutic option in fat transplantation. However, the detailed mechanisms underlying the function of BMSC-EVs remain to be investigated.

The present study was supported by the Major State Basic Research Development Program of China (grant no. 2011CB964704) and the National Natural Science Foundation of China (grant nos. 81271714 and 31170944).

![Characterization of bone marrow mesenchymal stem cell-derived EVs. (A) Morphological characteristics of the EVs, as revealed by scanning electron microscopy. Scale bar, 200 nm. (B) Size distribution of the EVs. (C) Surface profile of EVs, as determined by flow cytometry. Representative results from 3 independent experiments are presented. (D) Quantitative analysis of the flow cytometry results (n=3/group). EVs, extracellular vesicles; CD, cluster of differentiation.](MMR-16-03-3069-g00){#f1-mmr-16-03-3069}

![Internalization of BMSC-EVs by HUVECs. HUVECs were incubated with CM-Dil (red)-labeled BMSC-EVs for 2, 4 and 6 h. Cell nuclei were stained with DAPI (blue). Scale bar, 20 µm. BMSC-EVs, bone marrow mesenchymal stem cell-derived extracellular vesicles; HUVECs, human umbilical vein endothelial cells.](MMR-16-03-3069-g01){#f2-mmr-16-03-3069}

![BMSC-EVs increased HUVEC viability, tube formation and migration *in vitro*. (A) Viability of HUVECs in the absence (control) or presence of two concentrations of BMSC-EVs, as determined by Cell Counting Kit-8 assay. (B) Tube formation of HUVECs in the absence (control) or presence of two doses of BMSC-EVs. Scale bar, 200 µm. (C) Quantitative analysis of the vessel-like structures formed in response to the two doses of BMSC-EVs. (D) Cell migration of HUVECs in the absence (control) or presence of two concentrations of BMSC-EVs. Scale bar, 200 µm. (E) Quantitative analysis of the recovered area after a scratch test in response to two doses of BMSC-EVs (n=9/group). \*P\<0.05. BMSC-EVs, bone marrow mesenchymal stem cell-derived extracellular vesicles; HUVECs, human umbilical vein endothelial cells; OD, optical density.](MMR-16-03-3069-g02){#f3-mmr-16-03-3069}

![Bone marrow mesenchymal stem cell-derived extracellular vesicles improved fat graft retention. (A) Macroscopic images of the harvested fat grafts 12 weeks post-transplantation. (B) Quantitative analysis of the tissue volume of the fat grafts (n=9/group). (C) Quantitative analysis of the wet weight of the fat grafts (n=9/group). \*P\<0.05.](MMR-16-03-3069-g03){#f4-mmr-16-03-3069}

![Histological analysis of fat grafts by H&E and Masson trichrome staining. Scale bar, 100 µm. H&E, hematoxylin and eosin.](MMR-16-03-3069-g04){#f5-mmr-16-03-3069}

![Angiogenesis was evaluated by anti-cluster of differentiation 31 staining. Grafts from the EV-treated groups exhibited significantly increased numbers of vessels compared with in the control group. Scale bar, 100 µm. \*P\<0.05. EVs, extracellular vesicles.](MMR-16-03-3069-g05){#f6-mmr-16-03-3069}

![Expression of the proangiogenic growth factors (A) PDGF-A, (B) PDGFR-A, (C) VEGF-A and (D) TGF-β. in fat grafts, as determined by reverse transcription-quantitative polymerase chain reaction. Each sample was tested in triplicate (n=3/group). EVs, extracellular vesicles; PDGF-A, platelet-derived growth factor α; PDGFR-A, platelet-derived growth factor receptor α; VEGF-A, vascular endothelial growth factor A; TGF-β, transforming growth factor β. \*P\<0.05.](MMR-16-03-3069-g06){#f7-mmr-16-03-3069}

###### 

Primers used in quantitative polymerase chain reaction analysis.

  Gene      Primer size (bp)   Primer sequences
  --------- ------------------ -----------------------------
  PDGF-A    199                F:GCAAGACCAGGACGGTCATTTAC
                               R:GGCTTCTTCCTGACATACTC
  PDGFR-A   193                F:CCATGCAGTTGCCTTACGAC
                               R:AGAGCCTGCTTTTCACTAGACC
  VEGF-A    130                F:GGAGATCCTTCGAGGAGCACTT
                               R:GGCGATTTAGCAGCAGATATAAGAA
  TGF-β     226                F:AACCCCCATTGCTGTCCCGTG
                               R:GCGCTGAATCGAAAGCCCTGT
  GAPDH     235                F:GACTTCAACAGCAACTCCCAC
                               R:TCCACCACCCTGTTGCTGTA

PDGF-A, platelet-derived growth factor α; PDGFR-A, platelet-derived growth factor receptor α; VEGF-A, vascular endothelial growth factor A; TGF-β, transforming growth factor β; F, forward; R, reverse.
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